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Venous	thromboembolism	(VTE)	is	a	multifactorial	
disease,	which	may	appear	as	deep	venous	 throm-
bosis	(DVT)	of	lower	or	upper	limb,	abdominal	deep	
venous	thrombosis	and/or	pulmonary	embolism	(PE).	
Of	course,	PE	represent	the	most	dangerous	clinical	
manifestation	and	it	may	be	classified	as	non-massive	
PE	or	massive	PE	that	may	lead	to	severe	impairment	
of	gas	exchange	and	pulmonary	hypertension	induc-
ing	right	ventricular	dysfunction	and/or	heart	failure	
then	 to	be	 fatal	within	 the	 first	30	min	of	 symptom	
onset	[1].
However,	VTE	recognizes	 inherited	and	acquired	
risk	factors	and	cancer	is	the	most	common	acquired	
thrombotic	risk	factor	since	Trousseau	described	this	
clinical	association	 for	 the	 first	 time	 in	1865.	On	 the	
other	hand	oncological	patients	with	concurrent	VTE	
are	more	at	risk	according	to	the	data	reported	by	So-
rensen	at	al.	[2].
Furthermore,	during	 the	natural	history	of	onco-
logical	disease	other	thrombotic	risk	factors	may	be	
involved,	so	inducing	a	strong	increase	of	VTE	risk	for	
oncological	patients.	This	short	review	is	focused	to	
the	evaluation	of	the	main	thrombotic	risk	factors	 in	
oncological	patients.
CanCer assoCiated thrombophilia
Malignancy	usually	shows	prothrombotic	properties	
per se	related	to	the	release	of	various	prothrombotic	
molecules	such	as	 tissue	 factor	 (TF)	and/or	cancer	
prococoagulant	(CP)	from	malignant	cells	[3].
CP	 is	cysteine	proteinase	produced	by	different	
types	of	malignant	 cells	 that	may	directly	 activate	
clotting	factor	X	without	the	involvement	of	clotting	VII	
pathway	[3].
Yet,	cancer	cells	may	also	express	and	release	TF	
their	 self	 so	 inducing	an	hyperactivation	of	clotting	
cascade	 via	 clotting	 factor	VII	 pathway	 [3].	More-
over,	TF	can	also	be	expressed	by	endothelial	cells	
or	monocytes/macrophages	because	 the	 involve-
ment	of	cytokine	network	related	to	tumor	growth,	in	
particular,	interleukin-1β	and	tumor	necrosis	factor	α	
[3].	Furthermore,	also	release	of	clotting	factor	X	by	
malignant	cells	has	been	rarely	described	[4].
Other	molecular	alterations	associated	with	tumor	
growth	and	progression	may	be	related	to	the	involve-
ment	 of	 fibrinolytic	 system.	A	 specific	 interaction	
between	cancer	cells	 and	extracellular	matrix	 has	
been	described	because	an	impairment	of	protease/
antiprotease	balance	causing	an	increased	injury	of	
extracellular	matrix	[5].	This	impairment	may	modify	
the	ability	of	cancer	cells	to	the	expansion	also	in	the	
extracellular	matrix	so	increasing	the	power	of	malig-
nant	growth	and	metastasis	[5].
The	 effect	 of	 described	 activities	 is	 a	 cancer	
acquired	 thrombophilia	 that	may	also	be	divided	 in	
subclinical	thrombophilia	(i.	e.	hypercoagulable	state)	
and	clinical	thrombophilia	in	which	we	may	recognise	
an	ongoing	thrombotic	event	(e.	g.	VTE)	[6].
CanCer and hyperCoagulable state
A	 subclinical	 hypercoagulable	 state	 has	 been	
already	described	in	oncological	patients	by	several	
authors	 in	 the	 literature.	Several	 tests,	 in	 fact,	may	
testify	 the	acquired	hypercoagulable	state	present	
in	cancer	such	as	 increased	 levels	of	d-dimer,	pro-
thrombin	fragment	1	+	2	and/or	thrombin-antithrombin	
complexes	[7].	Although,	we	previously	reported	the	
underlying	molecular	mechanisms	 responsible	 for	
cancer	acquired	thrombophilia,	also	other	conditions	
have	been	described	in	the	literature.	Some	report,	in	
fact,	described	an	acquired	protein	C	resistance	[8]	
and/or	increased	levels	of	fibrinogen	[9];	on	the	other	
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hand	also	hypofibrinolysis	due	 to	 impaired	 levels	of	
plasminogen	activator	inhibitor	type	1	and/or	type	2	
has	been	reported	[10–11].
A	clinical	hypercoagulable	state	may	be	defined	
as	 the	clinical	 thrombotic	manifestation	 (e.	g.	VTE)	
triggered	by	cancer	acquired	thrombophilia.	On	this	
topic	we	usually	may	find	a	venous	thromboembolism	
but	also	other	clinical	manifestation	such	as	arterial	
thrombosis	[12]	or	disseminated	intravascular	coagu-
lation	[13]	may	be	detected.	However,	in	the	last	years	
several	studies	have	underlined	 the	association	be-
tween	cancer	and	VTE	in	order	to	promote	also	further	
studies	on	thromboprophylaxis	of	VTE	in	oncological	
patients	[14–15].	Moreover,	on	this	 topic	we	should	
underline	that	VTE	may	appear	usually	as	DVT	of	lower	
limb	with	following	PE,	but	also	unusual	site	of	venous	
thrombosis	during	malignancy	was	described,	such	as	
abdominal	deep	vein	thrombosis	and/or	spontaneous	
upper	limb	DVT.
CliniCal Conditions assoCiated 
with vte in onCology
Type of cancer.	Since	Trousseau	described	for	
the	 first	 time	 the	association	between	cancer	and	
thrombosis,	several	authors	associated	particular	type	
of	cancer	 to	 thrombotic	complication.	On	 this	 field	
Levitan	et	al.	[16]	confirmed	that	such	type	of	cancer	
is	more	at	risk	of	VTE	complications	such	as	pancreatic	
cancer,	ovarian	cancer	or	cancer	localised	to	central	
nervous	system.
Yet,	further	study	underlined	also	another	interest-
ing	aspect	of	oncological	disease	such	as	the	staging.	
Advanced	stage	of	oncological	malignancy	have	been	
more	frequently	associated	with	VTE	[17]	if	compared	
to	early	stage	of	malignancy.
Oncological surgery.	Surgical	procedures	are	
the	most	common	known	risk	factor	for	VTE.	The	as-
sociation	between	major	surgery	and	VTE,	in	fact,	has	
been	underlined	by	long	time.	Yet,	surgical	approach	
is	usually	 related	 to	post-surgical	bed	 rest	so	add-
ing	another	 thrombotic	 risk	 factor.	However,	on	 this	
topic	authors	described	a	more	common	association	
between	oncological	surgery	and	VTE	if	compared	to	
non-oncological	surgery,	although	double	blind	ran-
domised	trial	on	these	issues	are	lacking.	Of	course,	
benefits	of	 thromboprophylaxis	 to	prevent	VTE	 for	
surgical	management	are	clear	for	both	oncological	
and	non-oncological	major	surgery	and	have	been	
demonstrated	by	several	studies	available	in	the	lite-
rature	[18–22].
Chemotherapy and other treatments. VTE	has	
been	already	underlined	in	patients	ongoing	chemo-
therapy.	First	studies	are	available	in	the	literature	since	
1980	and	are	 focused	mainly	on	patients	affected	
by	breast	cancer	 in	particular	 in	advanced	stage	of	
disease	[23–24].	In	the	following	years	several	other	
studies	focused	the	role	of	chemotherapy	as	additional	
risk	 factor	 for	VTE	 in	particular	during	 treatment	of	
haematological	malignancies.
Furthermore,	 also	 specific	 drugs	 have	 been	
frequently	 involved	 in	pathophysiology	of	acquired	
thrombophilia	during	chemotherapy.	A	common	ex-
perience	has	been	given	by	chemotherapy	for	breast	
cancer	based	on	CMF	regimen.	CMF,	but	also	other	
chemotherapeutical	regimen,	showed	to	reduce	the	
levels	of	natural	anticoagulant	such	as	protein	C	and	
protein	S	 in	particular	 if	associated	with	administra-
tion	of	tamoxifen	[25].	Tamoxifen	and	other	hormonal	
drugs,	 in	 fact,	associated	with	chemotherapy,	have	
been	reported	by	several	studies	 in	the	 literature	as	
thrombotic	risk	factors	[25].
On	the	other	hand,	also	growth	colony	stimulating	
factors	(G-CSF)	to	fight	chemotherapy-induced	neu-
tropenia	showed	a	prothrombotic	action	[26].
Yet,	in	the	last	10	years	also	thalidomide	has	been	
frequently	 associated	with	 thrombotic	 complica-
tion	during	chemotherapy,	while	pathophysiological	
mechanisms	 involved	are	still	 the	matter	of	discus-
sion	[27].
Central venous catheters and thrombosis.	
Central	venous	catheterisation	is	actually	well	estab-
lished	procedure	in	patients	affected	by	malignancy	
in	order	to	simplify	delivery	of	several	therapies	such	
as	chemotherapy,	as	blood	transfusion	and/or	blood	
products	administration,	as	parenteral	nutrition,	as	
fluids	and	other	medication,	in	particular	if	peripheral	
venous	accesses	are	lacking.
From	 this	point	of	 view	we	may	distinguish	cen-
tral	 venous	 catheter	 (CVC)	 in	 central	 venous	 line	
(e.	g.	subclavian	or	jugular	veins)	or	port-a-cath	(PaC).	
However,	since	these	procedures	have	been	adopted	
an	increased	number	of	complications	such	as	throm-
bosis	and/or	infections	have	been	pointed	out.
We	may	distinguish	two	several	types	of	catheter-
related	thrombosis:	a	sleeve	thrombosis	on	the	outside	
of	central	venous	catheter	or	a	vascular	thrombosis	
in	which	also	 the	vein	 is	 involved	by	 the	 thrombotic	
complication	of	CVC/PaC	[28].
For	 this	 reason	we	observed	also	an	 increased	
incidence	of	upper	 limb	DVT	 in	 the	 last	decades	 if	
compared	with	previous	data	available	in	the	literature	
in	which	this	kind	of	venous	thrombosis	has	been	con-
sidered	rare	[29].	From	a	clinical	point	of	view	usually	
thrombotic	complication	of	CVC/PaC	are	DVT	of	upper	
limb	with	frequent	involvement	of	all	the	venous	axis	
(e.	g.	extended	venous	thrombosis	of	axillar-subcla-
vian	and	 internal	 jugular	axis)	and	 this	 is	a	 relevant	
data	because	subclavian	and	internal	jugular	DVT	are	
frequently	associated	with	PE.
Concomitant medical illness. Several	patients	
affected	by	cancer	may	be	affected	by	further	medical	
illness	that	may	lead	to	a	further	increase	of	risk	of	VTE.	
In	these	conditions	we	should	include	first	of	all	recent	
immobility	due	to	acute	medical	illness.	Of	course,	im-
mobility	of	oncological	patients	may	be	due	to	cancer	
disease	per se,	but	frequently	other	conditions	such	as	
side	effects	of	cancer	therapies	or	following	medical	
illness	are	present.	Recent	studies,	in	fact,	underlined	
also	medical	illness,	in	particular	if	prolonged	bed	rest	
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is	required,	as	additional	risk	factors	for	VTE	in	cancer	
patients	such	as	severe	 infections,	as	heart	 failure,	
as	chronic	lung	injury,	as	neurological	disorders.	The	
MEDENOX	study	[30],	in	fact,	focused	these	clinical	
conditions	alone	or	associated	with	oncological	dis-
ease	as	relevant	risk	factor	for	VTE	in	patients	admitted	
in	hospital.
Inherited thrombophilia. A	clear	 association	
between	 inherited	 thrombophilia	and	malignancy	 for	
oncological	patients	affected	by	VTE	has	not	been	
investigated	by	large	studies.	However,	several	reports	
available	in	the	literature	showed	that	subjects	carriers	
of	 inherited	 thrombophilia	may	not	only	show	an	 in-
creased	incidence	of	thrombotic	complications	but	also	
of	relapse	of	VTE	if	affected	by	malignancy,	if	compared	
with	subjects	with	malignancy	and	without	 thrombo-
philia.	Yet,	a	preliminary	report	focused	on	upper	limb	
DVT	seems	to	underline	a	possible	association	between	
thrombophilia	and	malignancy	[31].	On	the	other	hand,	
a	 recent	study	based	on	a	 larger	population	did	not	
confirm	the	association	between	 inherited	 thrombo-
philia	and	VTE	in	patients	affected	by	malignancy	[32].	
However,	this	study	focused	all	venous	thromboembolic	
events	and	not	only	upper	limb	DVT.
So,	further	studies	are	needed	to	understand	the	
possible	link	and	the	effective	role	of	inherited	throm-
bophilia	in	oncological	patients.
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Молекулярные и клинические характеристики, 
ассоциированные с венозной троМбоэМболией 
у онкологических больных 
Связь между опухолевым процессом и гематогенной тромбофилией известна с 1865 г., когда Trousseau впервые дал ее описа-
ние. В последнее время отмечают возрастающий интерес к этой проблеме и связанным с ней молекулярным и клиническим 
параметрам, которые учитываются при постоянном наблюдении за больными онкологического профиля. Данный короткий 
обзор литературы посвящен характеристике молекулярных факторов, лежащих в основе тромбофилии, возникающей 
в процессе развития новообразований, а также другим особенностям клинического течения, индуцирующим тромбофилию 
у больных онкологического профиля, таким как хирургическое вмешательство, химиотерапия, сопутствующие осложнения 
и наследственная тромбофилия.
Ключевые слова: рак, тромбофилия, гиперсвертываемость, наследственная тромбофилия, химиотерапия.
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